Woodworth, Kate R;
Moulia, Danielle;
Collins, Jennifer P;
Hadler, Stephen C;
Jones, Jefferson M;
Reddy, Sujan C;
Chamberland, Mary;
Campos-Outcalt, Doug;
Morgan, Rebecca L;
Brooks, Oliver;
Talbot, H. Keipp;
Lee, Grace M;
Bell, Beth P;
Daley, Matthew F;
Mbaeyi, Sarah;
Dooling, Kathleen;
Oliver, Sara E.
The Pfizer-BioNTech COVID-19 (BNT162b2) vaccine is a lipid nanoparticle–formulated, nucleoside-modified mRNA vaccine encoding the prefusion spike glycoprotein of SARS-CoV-2, the virus that causes COVID-19. On August 23, 2021, the Food and Drug Administration (FDA) approved a Biologics License Applicati...
Fleming-Dutra, Katherine E;
Wallace, Megan;
Moulia, Danielle L;
Twentyman, Evelyn;
Roper, Lauren E;
Hall, Elisha;
Link-Gelles, Ruth;
Godfrey, Monica;
Woodworth, Kate R;
Anderson, Tara C;
Rubis, Amy B;
Shanley, Edwin;
Jones, Jefferson M;
Morgan, Rebecca L;
Brooks, H. Oliver;
Talbot, Keipp;
Lee, Grace M;
Bell, Beth P;
Meyer, Sarah;
Daley, Matthew;
Oliver, Sara E.
On June 17, 2022, the Food and Drug Administration (FDA) issued Emergency Use Authorization (EUA) amendments for the mRNA-1273 (Moderna) COVID-19 vaccine for use in children aged 6 months–5 years, administered as 2 doses (25 µg [0.25 mL] each), 4 weeks apart, and BNT162b2 (Pfizer-BioNTech) COVID-19 va...
Wallace, Megan;
Moulia, Danielle;
Blain, Amy E;
Ricketts, Erin K;
Minhaj, Faisal S;
Link-Gelles, Ruth;
Curran, Kathryn G;
Hadler, Stephen C;
!Asif, Amimah;
Godfrey, Monica;
Hall, Elisha;
Fiore, Anthony;
Meyer, Sarah;
Su, John R;
Weintraub, Eric;
Oster, Matthew E;
Shimabukuro, Tom T;
Campos-Outcalt, Doug;
Morgan, Rebecca L;
Bell, Beth P;
Brooks, Oliver;
Talbot, H. Keipp;
Lee, Grace M;
Daley, Matthew F;
Oliver, Sara E.
The mRNA-1273 (Moderna) COVID-19 vaccine is a lipid nanoparticle-encapsulated, nucleoside-modified mRNA vaccine encoding the stabilized prefusion spike glycoprotein of SARS-CoV-2, the virus that causes COVID-19. During December 2020, the vaccine was granted Emergency Use Authorization (EUA) by the Food a...
Oliver, Sara E;
Wallace, Megan;
See, Isaac;
Mbaeyi, Sarah;
Godfrey, Monica;
Hadler, Stephen C;
Jatlaoui, Tara C;
Twentyman, Evelyn;
Hughes, Michelle M;
Rao, Agam K;
Fiore, Anthony;
Su, John R;
Broder, Karen R;
Shimabukuro, Tom;
Lale, Allison;
Shay, David K;
Markowitz, Lauri E;
Wharton, Melinda;
Bell, Beth P;
Brooks, Oliver;
McNally, Veronica;
Lee, Grace M;
Talbot, H. Keipp;
Daley, Matthew F.
On February 27, 2021, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the adenovirus-vectored COVID-19 vaccine (Janssen Biotech, Inc., a Janssen Pharmaceutical company, Johnson & Johnson), and on February 28, 2021, the Advisory Committee on Immunization Practices (A...
